CMK389

BIOLOGICAL2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Atopic DermatitisPulmonary Sarcoidosis

Phase 2

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

CompletedNCT04064242

Novartis PharmaceuticalsPulmonary Sarcoidosis

Start: 2020-09-23End: 2023-12-12Updated: 2025-04-13

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

CompletedNCT04836858

Novartis PharmaceuticalsAtopic Dermatitis

Start: 2021-04-20End: 2022-12-13Updated: 2024-06-20